Takeda’s Febuxostat Finally Gets U.S. Advisory Panel Review
This article was originally published in PharmAsia News
Executive Summary
Takeda North America's long-delayed investigational gout drug febuxostat, previously the subject of two "approvable" letters, will be reviewed by the U.S. FDA Arthritis Drugs Advisory Committee on Nov. 24